This case highlights the diagnostic and management challenges of refractory multisystem sarcoidosis progressing over a two-year period despite advanced biologic therapy.
🎯 Background & Rationale
- Malignant pleural effusion: Non-small cell lung cancer frequently causes malignant pleural effusion, signaling a poor prognosis and severe dyspnea.
- Role of lymphangiogenesis: While angiogenesis is heavily targeted in cancer, tumor lymphangiogenesis drives malignant pleural effusion formation via hyperpermeable lymphatic vessels.
- Drug repurposing gap: Itraconazole is known to suppress angiogenesis, but its specific therapeutic effect and mechanism on lymphangiogenesis in malignant pleural effusion remain unclear.
👥 Study Design & Population
- Preclinical animal study: A controlled in vivo murine intervention trial using a Lewis lung carcinoma pleural xenograft model.
- Experimental cohorts: Thirty BALB/c nude mice were randomized into three groups (10 mice per group) following tumor inoculation.
- Intervention arms: Mice received intrapleural injections of high-dose itraconazole (25 mg/kg), low-dose itraconazole (8 mg/kg), or hydroxypropyl-beta-cyclodextrin control.
📈 Methodology & Rigor
- Precise modeling: A stereomicroscope-guided pleural injection technique was utilized to minimize soft tissue and vascular damage during model creation.
- Multimodal evaluation: Evaluated outcomes via computed tomography scans, direct effusion volume measurement, tumor foci counts, and immunohistochemistry.
- Statistical approach: Data were expressed as mean ± standard deviation and analyzed using a one-way analysis of variance and Dunn’s test.
🔬 Key Findings [or Planned Endpoints]
- Reduced effusion volume: Mean malignant pleural effusion volume was significantly lower in the high-dose itraconazole group (311.19 ± 27.20 uL) compared to controls (575.76 ± 32.61 uL, P < 0.01).
- Fewer tumor foci: Pleural tumor foci counts were significantly decreased in the high-dose itraconazole group (11.55 ± 3.28) versus controls (27.40 ± 3.92, P < 0.001).
- Suppressed lymphangiogenesis: Lymphatic microvessel density and vascular endothelial growth factor-C expression were significantly reduced in the high-dose itraconazole group compared to controls (P < 0.001).
⚖️ Critical Appraisal
- Preclinical limitation: Findings are derived from a murine xenograft model using murine lung carcinoma cells, requiring caution before extrapolating to human non-small cell lung cancer.
- Local delivery route: Intrapleural administration maximized local drug concentration, but clinical translation would require evaluating systemic versus local dosing safety and efficacy.
- Mechanistic insight: The study successfully links itraconazole efficacy to vascular endothelial growth factor-C downregulation, offering a clear pathophysiological rationale for future trials.
💡 The Clinical Bottom Line
- Itraconazole effectively suppresses malignant pleural effusion formation in murine models by inhibiting tumor lymphangiogenesis and vascular endothelial growth factor-C expression.
- While these preclinical results highlight the potential of drug repurposing for malignant pleural effusions, randomized human clinical trials are necessary before changing practice in the interventional pulmonology suite.
Abstract
Keep reading
N opens the next oneClinicians should note that the presence of targetable mutations in non-small cell lung cancer with malignant pleural disease is not associated with improved survival, based on the findings from this study.
Shape-sensing robotic-assisted bronchoscopy achieved a strict diagnostic yield of 70.2% with a low pneumothorax rate of 3.3%, demonstrating that earlier tissue diagnosis of very small pulmonary nodules is feasible and safe for clinical practice.
CT-guided fiducial placement remains a relevant technique for pre-procedural localization of peripheral lung lesions.
This study introduces ultrasound-guided trans-cannula cryobiopsy of supraclavicular lymph nodes as a novel superficial lymph node approach for tissue acquisition in 10 consecutive patients, though specific numeric success or safety results were not provided in the abstract.
Active infection is not an absolute contraindication to endobronchial valve placement, but positive pressure ventilation significantly increases clinical failure odds with an aOR of 3.00 at P < 0.001.